2015/10/06 - Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that the Monitoring Board for the Phase IIa trial of drug candidate QGC001 – a group of independent experts tasked with regularly reviewing it and, if necessary, the tolerance data from the trial – met for the first time on 29 September 2015.

Download Press Release